MX2021012251A - Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). - Google Patents
Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc).Info
- Publication number
- MX2021012251A MX2021012251A MX2021012251A MX2021012251A MX2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A MX 2021012251 A MX2021012251 A MX 2021012251A
- Authority
- MX
- Mexico
- Prior art keywords
- region
- modified
- protein
- purifying
- modified antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente invención, se encontró una resina purificada por afinidad que tiene suficiente afinidad de unión por una región Fc modificada que tiene una capacidad de unión con proteína A reducida. Específicamente, se purificó con éxito inmunoglobulina que contiene una región Fc modificada que tiene capacidad de unión con proteína A reducida, caracterizado porque un ligando modificado con proteína A que incluye una estructura en la que se ha sustituido un aminoácido del dominio C sirve como ligando Fc.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019074738 | 2019-04-10 | ||
PCT/JP2020/015904 WO2020209318A1 (ja) | 2019-04-10 | 2020-04-09 | Fc領域改変抗体の精製方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012251A true MX2021012251A (es) | 2021-11-12 |
Family
ID=72752051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012251A MX2021012251A (es) | 2019-04-10 | 2020-04-09 | Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220213140A1 (es) |
EP (1) | EP3954696A4 (es) |
JP (1) | JPWO2020209318A1 (es) |
KR (1) | KR20210149779A (es) |
CN (1) | CN113906042A (es) |
AU (1) | AU2020273072A1 (es) |
BR (1) | BR112021020204A2 (es) |
CA (1) | CA3136398A1 (es) |
IL (1) | IL286982A (es) |
MX (1) | MX2021012251A (es) |
SG (1) | SG11202110986YA (es) |
TW (1) | TW202104244A (es) |
WO (1) | WO2020209318A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
JP6030452B2 (ja) | 2010-11-30 | 2016-11-24 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
US10000560B2 (en) | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69333823T2 (de) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | Verfahren zur herstellung von gliedern von spezifischen bindungspaaren |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CN101014619B (zh) | 2004-07-15 | 2010-11-03 | 赞科股份有限公司 | 优化的Fc变体 |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
PL1752471T3 (pl) | 2005-01-05 | 2009-04-30 | F Star Biotechnologische Forschungs Und Entw M B H | Syntetyczne domeny immunoglobulinowe o właściwościach wiążących konstruowanych w regionach cząsteczki różnych od regionów determinujących komplementarność |
WO2007097361A1 (ja) * | 2006-02-21 | 2007-08-30 | Protenova Co., Ltd. | イムノグロブリン親和性リガンド |
JP4179517B2 (ja) | 2006-02-21 | 2008-11-12 | プロテノバ株式会社 | イムノグロブリン親和性リガンド |
IN2014DN10515A (es) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
MX2010003450A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo modificada. |
ES2532461T3 (es) | 2007-12-26 | 2015-03-27 | Xencor, Inc. | Variantes de FC con enlazamiento alterado a FCRN |
DK2708559T3 (en) | 2008-04-11 | 2018-06-14 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of repeatedly binding two or more antigen molecules |
JP5229888B2 (ja) * | 2008-09-30 | 2013-07-03 | 独立行政法人産業技術総合研究所 | 弱酸性域での易解離性を向上したプロテインa変異型タンパク質及び抗体捕捉剤 |
TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
JP6030452B2 (ja) | 2010-11-30 | 2016-11-24 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
WO2012132067A1 (ja) | 2011-03-30 | 2012-10-04 | 中外製薬株式会社 | 抗原結合分子の血漿中滞留性と免疫原性を改変する方法 |
WO2012133349A1 (ja) * | 2011-03-25 | 2012-10-04 | 株式会社カネカ | アフィニティー分離マトリックス用タンパク質 |
TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
CN110639014A (zh) | 2011-09-30 | 2020-01-03 | 中外制药株式会社 | 促进抗原消除的抗原结合分子 |
US20150166654A1 (en) | 2012-05-30 | 2015-06-18 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
DK2857419T3 (da) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyle til eliminering af aggregerede antigener |
WO2014145159A2 (en) | 2013-03-15 | 2014-09-18 | Permeon Biologics, Inc. | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
JP6153801B2 (ja) | 2013-07-23 | 2017-06-28 | 旭化成ホームズ株式会社 | ノズル |
EP3042912A4 (en) * | 2013-09-04 | 2017-05-03 | Protenova Co., Ltd. | Immunoglobulin-binding domain multimer |
JP2015185254A (ja) | 2014-03-20 | 2015-10-22 | 日立マクセル株式会社 | 非水電解質二次電池 |
US10000560B2 (en) * | 2014-12-19 | 2018-06-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use |
TWI605057B (zh) | 2015-12-18 | 2017-11-11 | 中外製藥股份有限公司 | 抗肌抑素抗體、含變異fc區之多肽及使用方法 |
-
2020
- 2020-04-09 CA CA3136398A patent/CA3136398A1/en active Pending
- 2020-04-09 WO PCT/JP2020/015904 patent/WO2020209318A1/ja unknown
- 2020-04-09 AU AU2020273072A patent/AU2020273072A1/en active Pending
- 2020-04-09 CN CN202080034720.3A patent/CN113906042A/zh active Pending
- 2020-04-09 KR KR1020217035897A patent/KR20210149779A/ko active Search and Examination
- 2020-04-09 MX MX2021012251A patent/MX2021012251A/es unknown
- 2020-04-09 US US17/602,196 patent/US20220213140A1/en active Pending
- 2020-04-09 TW TW109111941A patent/TW202104244A/zh unknown
- 2020-04-09 JP JP2021513692A patent/JPWO2020209318A1/ja active Pending
- 2020-04-09 BR BR112021020204A patent/BR112021020204A2/pt unknown
- 2020-04-09 SG SG11202110986YA patent/SG11202110986YA/en unknown
- 2020-04-09 EP EP20787324.1A patent/EP3954696A4/en active Pending
-
2021
- 2021-10-05 IL IL286982A patent/IL286982A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3954696A4 (en) | 2023-07-26 |
BR112021020204A2 (pt) | 2021-12-07 |
KR20210149779A (ko) | 2021-12-09 |
CN113906042A (zh) | 2022-01-07 |
WO2020209318A1 (ja) | 2020-10-15 |
US20220213140A1 (en) | 2022-07-07 |
IL286982A (en) | 2021-12-01 |
JPWO2020209318A1 (es) | 2020-10-15 |
AU2020273072A1 (en) | 2021-12-09 |
EP3954696A1 (en) | 2022-02-16 |
CA3136398A1 (en) | 2020-10-15 |
SG11202110986YA (en) | 2021-11-29 |
TW202104244A (zh) | 2021-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012251A (es) | Metodo para purificar un anticuerpo modificado en la region de fragmento cristalizable (fc). | |
WO2018134235A8 (en) | Improved serum albumin binders | |
MX347818B (es) | Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero. | |
MX2023007520A (es) | Aglutinantes de albumina de suero mejorados. | |
MX2024008521A (es) | Aglutinantes de albumina serica mejorados. | |
EP4324840A3 (en) | Novel alkaline stable immunoglobulin-binding proteins | |
EA201791742A1 (ru) | Антитела, направленные против гена-3 активации лимфоцитов (lag-3) | |
WO2017085172A3 (en) | Improved serum albumin binders | |
MA38498A1 (fr) | Protéines de liaison anti-lag-3 | |
UA86605C2 (ru) | Антитело, которое содержит вариант исходного человеческого fс-участка | |
SG10201805584YA (en) | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB | |
MX2023006291A (es) | Metodos para purificar proteinas que contienen fc. | |
MX2020000288A (es) | Cromatografia. | |
MY188469A (en) | Low affinity blood brain barrier receptor antibodies and uses therefor | |
ATE525087T1 (de) | Verfahren zur aufreinigung von antikörpern | |
EP4371996A3 (en) | Methods for purifying antibodies | |
MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
PE20230348A1 (es) | Variantes de anticuerpos felinos | |
WO2015006337A3 (en) | Compositions and methods for increasing protein half-life in a serum | |
EP4349853A3 (en) | Novel triple-helical polypeptides lacking binding affinity for the fc domain of immunoglobulin and uses thereof | |
BR112021023540A2 (pt) | Agentes de afinidade | |
BR112014019773A8 (pt) | Ligantes para anticorpo e proteína de fusão fc para cromatografia de afinidade | |
MX2021015669A (es) | Anticuerpos para la unión a psma. | |
MX2018005831A (es) | Gradientes de ph-sal opuestos para separaciones de proteina mejoradas. | |
MX2021013441A (es) | Molecula de union a antigenos, composicion farmaceutica y metodo. |